News & Events
Stay up to date with the latest milestones, publications, conference appearances, and company news from myNEO. Learn more about our company or explore career opportunities.
Featured news and events timeline
First patient receives personalized cancer vaccine in NEOVACC Phase I trial
myNEO Therapeutics supports an important milestone in the NEOVACC Phase I clinical trial, with the first patient receiving a personalized therapeutic cancer vaccine for non-small cell lung cancer.
Read more →Events timeline
8Aug 1 2026
First patient receives personalized cancer vaccine in NEOVACC Phase I trial
myNEO Therapeutics supports an important milestone in the NEOVACC Phase I clinical trial, with the first patient receiving a personalized therapeutic cancer vaccine for non-small cell lung cancer.
Read more →
Jun 30 2026
A VIB-KU Leuven Collaboration to Advance Novel Breast Cancer Therapies
This is an important milestone in an exciting new strategic partnership between VIB and myNEO Therapeutics bringing novel breast cancer drugs to clinical stage development!
Read more →
Jun 2 2026
Built for speed: ImmunoEngine v5.5 & neoHUB v3.0
Time matters in personalized immunotherapy: every day saved between biopsy and treatment is a day gained for the patient.
Read more →
May 29 2026
touchImmunology Future Leader 2026
We're proud to share that our co-founder and CEO, Cedric Bogaert, has been named a touchIMMUNOLOGY Future Leader 2026 - selected by peers as one of the immunologists changing the future of precision medicine.
Read more →
Apr 28 2026
myNEO part of three multidisciplinary collaborative research programs
Excited to share that we are part of three multidisciplinary collaborative research programs to push the boundaries of next-generation immunotherapy
Read more →
Jan 19 2026
Strategic collaboration with VIB-CCB
We're excited to put into the spotlight our strategic collaboration with the VIB-KU Leuven Center for Cancer Biology (VIB-CCB) – a partnership that's pushing the boundaries of what's possible in precision oncology.
Read more →
Dec 8 2025
Wrapping up our second thematic week!
Last week, our team paused the day-to-day work for our annual deep-dive into new technologies and scientific insights to help shape our roadmap for the future.
Read more →
Sep 22 2025
New publication: neoIM, a predictive model for neoantigen immunogenicity
neoIM is the first-in-class immunogenicity predictor with high accuracy in identifying which neoantigens are capable of eliciting a T-cell response.
Read more →
Jun 11 2025
European Patent Office further protects myNEO's IP position and computational platform!
neoMS and neoIM – myNEO's proprietary algorithms for presentation and immunogenicity prediction – are the core of our ImmunoEngine pipeline.
Read more →